Indaptus (INDP) director exits Series AAA stake, trims Series AA

NodeGuardian

2026-03-28 05:42:25

Abstract generation in progress

Indaptus Therapeutics director David E. Lazar sold a significant portion of his convertible preferred stock in the company. He divested all 700,000 Series AAA Preferred Stock shares and 196,800 Series AA Preferred Stock shares through a Securities Purchase Agreement that closed on March 23, 2026. Following the transaction, he retained 103,200 shares of Series AA Preferred Stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.